Positron Emission Tomography-Computed Tomography (PET-CT) Versus No PET-CT in the Management of Potentially Resectable Colorectal Cancer Liver Metastases: Cost Implications of a Randomized Controlled Trial [BUSINESS OF ONCOLOGY]
Conclusion:
PET-CT was associated with limited clinical benefit and a nonsignificant increased cost. Universal funding of PET-CT in the management of patients with resectable colorectal cancer liver metastases does not seem justified. (Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Serrano, P. E., Gafni, A., Gu, C.-S., Gulenchyn, K. Y., Julian, J. A., Law, C., Hendler, A. L., Moulton, C.-A., Gallinger, S., Levine, M. N. Tags: Imaging, Epidemiology, Diagnosis & Staging, Surgery, Chemotherapy, Diagnosis & Staging, Surgery, Nuclear Medicine and PET, CT BUSINESS OF ONCOLOGY Source Type: research
Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer [CARE DELIVERY]
Conclusion:
This cohort of patients with cancer reported significant levels of emotional distress, financial distress, and overall distress. These factors were interrelated, with both financial and emotional distress contributing to overall distress. Interventions targeted at alleviating financial distress may help to decrease levels of overall distress. (Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Meeker, C. R., Geynisman, D. M., Egleston, B. L., Hall, M. J., Mechanic, K. Y., Bilusic, M., Plimack, E. R., Martin, L. P., von Mehren, M., Lewis, B., Wong, Y.-N. Tags: Quality of life, Caregiver, Family member, Cost of care, General public, Cost of care, Media, Patient, Survivor, Quality of Life CARE DELIVERY Source Type: research
Osseous Sarcoidosis Mimicking Metastatic Cancer on Positron Emission Tomography [Case Report]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Ashamalla, M., Koutroumpakis, E., McCarthy, L., Hegener, P., Grimm, R., Mehdi, S. Tags: Management and treatment, Imaging, Nuclear Medicine and PET, CT, MRI, General/Other Radiology Case Report Source Type: research
Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary [Guideline Summary]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Chuang, L. T., Temin, S., Berek, J. S. Tags: Clinical guidelines, Quality of care, ASCO Guidelines, Diagnosis & Staging, Surgery, Radiation, Chemotherapy Guideline Summary Source Type: research
E-Mail Communication Practices and Preferences Among Patients and Providers in a Large Comprehensive Cancer Center [CARE DELIVERY]
Conclusion:
E-mail is commonly used for patient care but is poorly documented. The use of e-mail in this setting can be developed with appropriate guidance; however, there may be concerns about widening the gap between certain groups of patients. (Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Cook, N., Maganti, M., Dobriyal, A., Sheinis, M., Wei, A. C., Ringash, J., Krzyzanowska, M. K. Tags: Communication, Doctor-patient communication, Access to care, Access to care, Information systems, Training, Quality of Care CARE DELIVERY Source Type: research
Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients [CARE DELIVERY]
Conclusion:
First-line carboplatin/etoposide is associated with similar survival and less subsequent hospital-based health care use than cisplatin/etoposide among elderly patients with ES SCLC treated in ambulatory settings. (Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Hatfield, L. A., Huskamp, H. A., Lamont, E. B. Tags: Quality of Care, Guidelines, Small Cell, Chemotherapy CARE DELIVERY Source Type: research
Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status? [CARE DELIVERY]
Conclusion:
Strong consensus among oncologists exists for chemotherapy in patients with advanced non–small-cell lung cancer and good performance status. However, the relatively high rate of chemotherapy recommendations for patients with poor performance status despite the unfavorable risk–benefit profile highlights the need for ongoing work to define high-value care in oncology and to implement and evaluate strategies to align incentives for such care. (Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Tisnado, D., Malin, J., Kahn, K., Landrum, M. B., Fletcher, R., Klabunde, C., Clauser, S., Rogers, S. O., Keating, N. L. Tags: Clinical guidelines, Management and treatment, Treatment related issues, Palliative care, Quality of care, General public, Patient, Quality of Care, Guidelines, Chemotherapy CARE DELIVERY Source Type: research
Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy [COMMENTARIES]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Vandeven, N. A., Nghiem, P. Tags: Clinical guidelines, Nonmelanoma Skin Cancer, Immunology/Immunobiology COMMENTARIES Source Type: research
Importance of Sentinel Lymph Node Biopsy in Merkel Cell Carcinoma [COMMENTARIES]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Angeles, C. V., Wong, S. L. Tags: Clinical guidelines, Management and treatment, Nonmelanoma Skin Cancer, Surgical Oncology COMMENTARIES Source Type: research
Recent Insights and Advances in the Management of Merkel Cell Carcinoma [Clinical Reviews]
Merkel cell carcinoma (MCC) is a rare and highly aggressive neuroendocrine malignancy with a propensity for recurrence and a poor prognosis. Incidence of MCC is on the rise and is known to increase with advanced age, immunosuppression, and UV exposure. Merkel cell polyomavirus is implicated in the pathogenesis of virus-positive MCC and accounts for 80% of MCCs in the northern hemisphere and 25% in southern latitudes. In contrast, tumorigenesis of virus-negative MCC is linked to UV-induced DNA damage. Interplay between ubiquitous Merkel cell polyomavirus skin infections that commonly occur in healthy skin and other establis...
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Banks, P. D., Sandhu, S., Gyorki, D. E., Johnston, M. L., Rischin, D. Tags: Nonmelanoma Skin Cancer Clinical Reviews Source Type: research
Allogeneic Hematopoietic Stem-Cell Transplantation in Myelofibrosis: Key Messages for Clinical Practice in the Era of Janus Kinase 1/2 Inhibitors [COMMENTARIES]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Kongtim, P., Popat, U. Tags: Hematology COMMENTARIES Source Type: research
Outcome Improvement After Allogeneic Stem-Cell Transplantation in Myelofibrosis [COMMENTARIES]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Kroger, N. Tags: Diagnosis & Staging, Chemotherapy COMMENTARIES Source Type: research
Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review [Clinical Reviews]
Myelofibrosis is a myeloproliferative neoplasm with cardinal features of extramedullary hematopoiesis, hepatosplenomegaly, cytopenias, and constitutional symptoms that result in shortened survival and leukemic transformation. It is a disease predominantly of the elderly, and currently available therapies only offer symptom control without curative benefit or ability to alter disease progression. Allogeneic hematopoietic stem-cell transplant (HSCT) is the only potentially curative intervention; however, this is only feasible in younger and medically fit patients and selectively offered to those with high-risk disease. Despi...
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Farhadfar, N., Cerquozzi, S., Patnaik, M., Tefferi, A. Tags: Leukemia, Hematology Clinical Reviews Source Type: research
Treatment of Stage IIIA Non-Small-Cell Lung Cancer: Charting the Next Steps [COMMENTARIES]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Senan, S. Tags: Diagnosis & Staging, Combined Modality COMMENTARIES Source Type: research
Multidisciplinary Treatment of Stage IIIA Non-Small-Cell Lung Cancer [COMMENTARIES]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Yendamuri, S. Tags: Hematology COMMENTARIES Source Type: research
